Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/GenVec+%28GNVC%29+Reports+Dosing+in+Novartis+%28NVS%29+Phase+12+Using+Bilateral+Hearing+Loss+Treatment+Tech/9951089.html for the full story.
GenVec, Inc. (GNVC)
Q4 2013 Earnings Conference Call
March 28, 2014 10:00 a.m. ET
Douglas Swirsky - President and CEO
Douglas Brough - Chief Scientific Officer
James Lambert - Senior Director of Accounting & Finance
NEW YORK (TheStreet) -- Shares of GenVec Inc. were up 12.83% to $2.99 in aftermarket trading Thursday. The jump comes ahead of the company posting its fiscal 2013 fourth quarter earnings on Friday.Consensus EPS forecast for the company is - 10...
In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on GenVec (NASDAQ: GNVC) with a Buy rating and $9.00 price target.
In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of GenVec...
GenVec, Inc. (Nasdaq: GNVC) $2.89. GenVec higher after reporting that on December 4, 2013, the National Institutes of Health's Recombinant DNA Advisory Committee (RAC) unanimously approved the protocol for initiation of a Phase 1...
ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) 59.2% LOWER; announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.